Business Context and Reporting Period
Healthcare Triangle, Inc. (HCTI), a Delaware corporation and emerging growth company, filed this Form 8-K on January 22, 2026. The report details the entry into a Material Definitive Agreement and the subsequent completion of an acquisition. The transaction involves the acquisition of two Spanish entities, Teyamé 360 S.L. and Datono Mediación S.L. (collectively, the "Acquired Companies"), by Teyame AI Holdings Inc., a wholly-owned subsidiary of the Company. The transaction closed on January 29, 2026, with an effective date of January 1, 2026.
Key Financial Metrics and Transaction Structure
The filing outlines a complex acquisition structure with an aggregate purchase price of up to $50.0 million. The consideration is split between cash, equity, and contingent earnouts:
- Total Purchase Price: Up to $50.0 million.
- Cash Consideration: $15.0 million total, structured as:
- $3.0 million (previously paid on December 3, 2025).
- $6.0 million (payable on or before January 29, 2026).
- $3.0 million (payable on April 29, 2026).
- $3.0 million (payable upon VAT clearances or six months post-agreement, no earlier than April 29, 2026).
- Equity Consideration: $30.0 million total, consisting of:
- $12.0 million in restricted common stock.
- $18.0 million in convertible preferred stock (subject to shareholder approval).
- Earnout: Up to $5.0 million in preferred stock for key management, contingent on gross revenue and EBITDA targets for fiscal years 2026 and 2027.
The number of shares issued is based on a "Base Price" (5-day VWAP prior to closing). The agreement includes a mechanism to limit total issuance to 19.99% of outstanding common stock, utilizing pre-funded warrants for any excess. The filing does not provide specific revenue, profit, cash flow, or debt metrics for the Company or the Acquired Companies.
Material Changes and Adjustments
The primary material change is the expansion of the Company's operations through the acquisition of the Spanish entities. The agreement includes specific provisions for price adjustments and share issuance modifications:
- Price Adjustment: If actual financial results of the Acquired Companies are less than projected amounts used for pricing, the Buyer may make a proportional downward adjustment to the purchase price.
- Reverse Stock Split Protection: If a reverse stock split occurs within 90 days of closing and the stock price remains below the Base Price for 10 consecutive trading days, the Company must issue additional shares to the sellers to maintain the original economic value.
- Restrictive Covenants: The sellers are subject to a two-year non-competition covenant post-closing.
Guidance, Risks, and Contingencies
Management commentary is limited to the announcement of the acquisition. Key risks and contingencies identified in the filing include:
- Performance Risk: The $5.0 million earnout is contingent on achieving specific annual gross revenue and EBITDA targets for 2026 and 2027.
- Regulatory and Tax Risk: A portion of the cash consideration ($3.0 million) is contingent on the Intermediary Seller obtaining VAT clearances and change-of-control waivers.
- Dilution Risk: The issuance of common stock and convertible preferred stock may dilute existing shareholders, though capped at 19.99% of pre-issuance outstanding shares.
- Valuation Risk: The final equity consideration is tied to the Company's stock price (VWAP) at closing, introducing volatility risk to the sellers and potential dilution risk to shareholders.
Investor Verification Checklist
- Verify the exact number of common and preferred shares issued based on the closing VWAP.
- Confirm the status of the $3.0 million cash tranche contingent on VAT clearances and bank account waivers.
- Review the specific gross revenue and EBITDA targets required to trigger the $5.0 million earnout.
- Assess the impact of the 19.99% issuance cap and the potential use of pre-funded warrants.
- Monitor for any downward price adjustments based on the post-closing financial review of the Acquired Companies.